The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group-Reference-Cited by-同舟云学术

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

Published:2018 Issue:1 Volume:57 Page:17-23
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Iriyama Noriyoshi¹,Ohashi Kazuteru²,Hashino Satoshi³,Kimura Shinya⁴,Nakaseko Chiaki⁵,Takano Hina⁶,Hino Masayuki⁷,Uchiyama Michihiro⁸,Morita Satoshi⁹,Sakamoto Junichi¹⁰,Sakamaki Hisashi²,Inokuchi Koiti¹¹

Affiliation:

1. Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan

2. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan

3. Health Care Center, Hokkaido University, Japan

4. Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan

5. Department of Hematology, Chiba University Hospital, Japan

6. Department of Hematology, Musashino Red Cross Hospital, Japan

7. Department of Hematology, Osaka City University Hospital, Japan

8. Department of Hematology, Suwa Red Cross Hospital, Japan

9. Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Japan

10. Tokai Central Hospital, Japan

11. Department of Hematology, Nippon Medical School, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/1/57_9035-17/_pdf

Reference28 articles.

1. 1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006.

2. 2. Tauchi T, Kizaki M, Okamoto S, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 35: 585-590, 2011.

3. 3. Ohnishi K, Nakaseko C, Takeuchi J, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 103: 1071-1078, 2012.

4. 4. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500-4505, 2005.

5. 5. Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68: 9809-9816, 2008.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

2. Long-term follow-up of efficacy and safety in elderly patients with chronic myeloid leukemia treated with intermittent low dose dasatinib therapy;Leukemia Research Reports;2024

3. Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia;Pharmaceutical Research;2023-09-19

4. Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Main Objectives, Design, and Expected Results;Clinical oncohematology;2022

5. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review;World Journal of Clinical Oncology;2021-02-24